Bone Pelvis
| Primary Site | Histology |
|---|---|
| C414 | 8000-8934, 8940-9138, 9141-9582 |
Notes
8000-8934, 8940-9138, 9141-9582
C414 Pelvic bones, sacrum, coccyx and associated joints
Note 1: Sources used in the development of this schema
- SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)
- SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)
- Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx
- Chapter 38 Bone, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.
Note 2: Bone is subdivided into three separate schemas
- Bone Appendicular Skeleton: C400-C403, C408-C411, C413, C418-C419
- Bone Spine: C412
- Bone Pelvis: C414
Note 3: Other EOD Schemas with Bone sites
- GIST: 8935-8936
- Kaposi Sarcoma: 9140
- Mycosis Fungoides: 9700-9701
Data Items
| Name | Default Value | Used in Derivation | NAACCR Item | Required By | Metadata |
|---|---|---|---|---|---|
| Year of Diagnosis | <BLANK> | No |
NAACCR #390
dateOfDiagnosis |
None | |
| Primary Site | <BLANK> | Yes |
NAACCR #400
primarySite |
None | |
| Histology | <BLANK> | Yes |
NAACCR #522
histologicTypeIcdO3 |
None | |
| Tumor Size Clinical | <BLANK> | No |
NAACCR #752
tumorSizeClinical |
None | |
| Tumor Size Pathological | <BLANK> | No |
NAACCR #754
tumorSizePathologic |
None | |
| Tumor Size Summary | 999 | Yes |
NAACCR #756
tumorSizeSummary |
None | |
| Regional Nodes Positive | 99 | No |
NAACCR #820
regionalNodesPositive |
None | |
| Regional Nodes Examined | 99 | No |
NAACCR #830
regionalNodesExamined |
None | |
| RX Summ Surgery/Radiation Sequence | <BLANK> | No |
NAACCR #1380
rxSummSurgRadSeq |
None | |
| RX Summ Systemic/Surgery Sequence | <BLANK> | No |
NAACCR #1639
rxSummSystemicSurSeq |
None | |
| Neoadjuvant Therapy | 9 | No |
NAACCR #1632
neoadjuvantTherapy |
None | |
| Neoadjuvant Therapy – Clinical Response | 9 | No |
NAACCR #1633
neoadjuvTherapyClinicalResponse |
None | |
| Neoadjuvant Therapy – Treatment Effect | 9 | No |
NAACCR #1634
neoadjuvTherapyTreatmentEffect |
None | |
| EOD Primary Tumor | 999 | Yes |
NAACCR #772
eodPrimaryTumor |
None | |
| EOD Regional Nodes | 999 | Yes |
NAACCR #774
eodRegionalNodes |
None | |
| EOD Mets | 00 | Yes |
NAACCR #776
eodMets |
None | |
| SS2018 | <BLANK> | No |
NAACCR #764
summaryStage2018 |
None | |
| Grade Clinical | 9 | Yes |
NAACCR #3843
gradeClinical |
All | SSDI |
| Grade Pathological | 9 | Yes |
NAACCR #3844
gradePathological |
All | SSDI |
| Grade Post Therapy Clin (yc) | <BLANK> | No |
NAACCR #1068
gradePostTherapyClin |
COC NPCR SEER |
SSDI |
| Grade Post Therapy Path (yp) | <BLANK> | No |
NAACCR #3845
gradePostTherapy |
CCCR/Canada COC NPCR SEER |
SSDI |
| Post Neoadj Chemo Percent Necrosis | XXX.8 | No |
NAACCR #3908
percentNecrosisPostNeoadjuvant |
CCCR/Canada COC SEER (RC) |
SSDI |